25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

19 October 2019 - Event

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

24 April 2019 - Basilea Pharmaceutica International Ltd.

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

"We are very much looking forward to the collaboration with Forge to develop truly innovative new antibiotics," commented Dr. Laurenz…

BEAM News
Member News
Events

Latest news of BEAM Alliance

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

24 September 2018 - BEAM Alliance

Antibiorésistance : BEAM Alliance tire la sonnette d’alarme

Priorités : Alerter les pouvoirs publics sur le besoin médical et l’urgence associés à la pénurie de nouveaux traitements contre…

07 June 2018 - BEAM Alliance

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed…

05 April 2018 - BEAM Alliance

EU-JAMRAI: BEAM Alliance becomes a new stakeholder

EU-JAMRAI [EU Joint Action on Antimicrobial Resistance (AMR) & Healthcare-Associated Infections (HCAI)] invited BEAM Alliance to take part as a new…

07 March 2018 - BEAM Alliance

BEAM Alliance speaking at the 10th Community of Users Meeting – Health session “Preparedness and response to Infectious Disease Threats” in Brussels

Florence Séjourné, President of the BEAM Alliance, presents the SME position in a round table on medical countermeasures towards policy…

page 1/2

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

22 May 2019 - MaaT Pharma

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

“Our lead therapeutic, MaaT013, developed using our MMRB platform, has already yielded promising safety data in our ongoing Phase 2…

21 May 2019 - MEDINA

Prokaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic Compounds

MEDINA is an internationally recognized leader in antimicrobial drug discovery and preclinical development and has contributed significantly to some of…

21 May 2019 - Motif Bio plc

Motif Bio to Present Iclaprim Data at ASM Microbe 2019

Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening…

16 May 2019 - DEINOVE

DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837

DNV3837 is a first-in-class antibiotic candidate targeting the treatment of Clostridioides difficile infections (CDIs), a disease classified as a priority…

03 May 2019 - Combioxin SA

Combioxin SA announcement: The Lancet Infectious Diseases publishes the first clinical results with CAL02

CAL02 is a disruptive, non-antibiotic drug addressing the severity and complications of infections. It consists of liposomes engineered to catch…

24 April 2019 - Basilea Pharmaceutica International Ltd.

Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics

"We are very much looking forward to the collaboration with Forge to develop truly innovative new antibiotics," commented Dr. Laurenz…

page 1/13

Events

19 October 2019

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

25 September 2019

Phage Futures Europe

Translating phage-based applications into clinically and commercially viable therapeutics

03 September 2019

ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority…

09 July 2019

GARDP webinar: Infection models for antimicrobial R&D: Intracellular models

In this webinar, Françoise van Bambeke, Research Director Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Catholic University of Louvain…

11 June 2019

GARDP webinar: Models for antimicrobial R&D: Development and use of in vivo models for infectious disease research

In this webinar, William J. Weiss, Director, PreClinical Services, University of North Texas System College of Pharmacy, will introduce experimental…

05 June 2019

Advancing Data Technologies to corner Antimicrobial Resistance

Antimicrobial resistance (AMR) already now is the largest global threat to Health and Food Safety (source: WHO). Without the focused…

03 June 2019

BIO International Convention

The key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO…

03 June 2019

6th World Congress and Exhibition on Antibiotics and Antibiotic Resistance

Theme: Challenges and New Concepts in Antibiotics Research

23 May 2019

Global Scale-up Program: Venture Scaling Strategy & Preparation

Venture assessment and individual intake Scale-up Entrepreneurial Finance Scale-up Entrepreneurial Marketing & Global Strategy

page 1/3